Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+1.48%
$74.71
100% positive prob.
5-Day Prediction
+4.42%
$76.88
100% positive prob.
20-Day Prediction
+3.55%
$76.23
95% positive prob.
SEC 8-K filings with transcript text
Feb 27, 2026 · 100% conf.
1D
+1.48%
$74.71
Act: +2.17%
5D
+4.42%
$76.88
20D
+3.55%
$76.23
ani-202602270001023024FALSE00010230242026-02-272026-02-27
Washington D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of Earliest Event Reported): February 27, 2026
(Exact name of registrant as specified in its charter)
Delaware001-3181258-2301143 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
210 Main Street West Baudette, Minnesota 56623 (Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (218) 634-3500 Not Applicable (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockANIPNasdaq Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition
On February 27, 2026, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*
Item 9.01Exhibits
(d)Exhibits
Exhibit No.Description 99.1Press Release of the Company, dated February 27, 2026
104Cover Page Interactive Data File (embedded with the Inline XBRL document)
*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 27, 2026
By:/s/ Stephen P. Carey Name:Stephen P. Carey Title:Senior Vice President Finance and Chief Financial Officer
Jan 12, 2026 · 100% conf.
1D
+1.48%
$74.71
Act: +2.17%
5D
+4.42%
$76.88
20D
+3.55%
$76.23
ani-202601120001023024FALSE00010230242026-01-122026-01-12
Washington D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026
(Exact name of registrant as specified in its charter)
Delaware001-3181258-2301143 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
210 Main Street West Baudette, Minnesota 56623 (Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (218) 634-3500 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockANIPNasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition
On January 12, 2026, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, as well as preliminary 2026 financial guidance. A copy of the press release is furnished herewith as Exhibit 99.1.*
The selected financial results are based on preliminary unaudited information and management estimates, are not a comprehensive statement of the Company’s financial results for either the fourth quarter or fiscal year ended December 31, 2025 and are subject to change. Such changes may be material. Our independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or provide any other form of assurance with respect to, these preliminary results.
In addition, on January 13, 2026, Nikhil Lalwani, President & CEO of the Company, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. A copy of the investor presentation is attached as Exhibit 99.2 hereto and incorporated herein by reference.*
Item 7.01 Regulation FD Disclosure
The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
Item 9.01Exhibits
(d)Exhibits
Exhibit No.Description 99.1Press Release of the Company, dated January 12, 2026
99.2Investor Presentation, dated January 2026
104Cover Page Interactive Data File (embedded with the Inline XBRL document)
*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 12, 2026ANI PHARMACEUTICALS, INC.
By:/s/ Stephen P. Carey Name:Stephen P. Carey Title:Senior Vice President Finance and Chief Financial Officer
Nov 10, 2025
ani-202511100001023024FALSE00010230242025-11-102025-11-10
Washington D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of Earliest Event Reported): November 10, 2025
(Exact name of registrant as specified in its charter)
Delaware001-3181258-2301143 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
210 Main Street West Baudette, Minnesota 56623 (Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (218) 634-3500 Not Applicable (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common StockANIPNasdaq Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02Results of Operations and Financial Condition
On November 10, 2025, ANI Pharmaceuticals, Inc. (the “Company”) published an updated investor presentation to the investor relations section of its website. The Company may use the updated presentation in various meetings with investors, analysts, and others from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*
Item 7.01 Regulation FD Disclosure
The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*
Item 9.01Exhibits
(d)Exhibits
Exhibit No.Description 99.1Investor Presentation, dated November 2025
104Cover Page Interactive Data File (embedded with the Inline XBRL document)
*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 10, 2025ANI PHARMACEUTICALS, INC.
By:/s/ Stephen P. Carey Name:Stephen P. Carey Title:Senior Vice President Finance and Chief Financial Officer
This page provides ANI Pharmaceuticals Inc. (ANIP) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ANIP's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.